ETHYL-2-METHYL-2-( (2-CHLORO-4-FORMYL) PHENOXY) PROPANOATE | 639784-42-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ETHYL-2-METHYL-2-( (2-CHLORO-4-FORMYL) PHENOXY) PROPANOATE
• 英文别名: Ethyl 2-(2-chloro-4-formylphenoxy)-2-methylpropanoate
• CAS: 639784-42-2
• 化学式: C₁₃H₁₅ClO₄
• 分子量: 270.713
• InChiKey: AJMPGXCLXRPHCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ETHYL-2-METHYL-2-( (2-CHLORO-4-FORMYL) PHENOXY) PROPANOATE 在 sodium tetrahydroborate 、 三溴化磷 、 甲胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 [ETHYL-2-METHYL-2-R2-CHLORO-4-(N-(METHVL) AMINOMETHYL) PHENOXVLPROPANOATE]
  参考文献：
  名称：

  [EN] PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS
  [FR] COMPOSES CHIMIQUES

  摘要：

  公开号：

  WO2004000785A3
• 作为产物：
  描述：

  3-氯-4-羟基苯甲醛 在 potassium carbonate 、 2-溴-2-甲基丙酸乙酯 作用下， 以 丙酮 为溶剂， 反应 19.5h， 以25.91%的产率得到ETHYL-2-METHYL-2-( (2-CHLORO-4-FORMYL) PHENOXY) PROPANOATE
  参考文献：
  名称：

  [EN] PHENYLOXYALKANONIC ACID DERIVATIVES AS HPPAR ACTIVATORS
  [FR] COMPOSES CHIMIQUES

  摘要：

  公开号：

  WO2004000785A3

文献信息

• Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis
  作者：Zhiqi Feng、Jiehao Xiang、Hui Liu、Jiaxin Li、Xiangrui Xu、Gang Sun、Runan Zheng、Shangran Zhang、Junlong Liu、Shanlin Yang、Qinglong Xu、Xiaoan Wen、Haoliang Yuan、Hongbin Sun、Liang Dai

  DOI：10.1021/acs.jmedchem.1c02002

  日期：2022.2.10

  receptors α/δ (PPARα/δ) are regarded as potential therapeutic targets for nonalcoholic steatohepatitis (NASH). However, PPARα/δ dual agonist GFT-505 exhibited poor anti-NASH effects in a phase III clinical trial, probably due to its weak PPARα/δ agonistic activity and poor metabolic stability. Other reported PPARα/δ dual agonists either exhibited limited potency or had unbalanced PPARα/δ agonistic activity

  过氧化物酶体增殖物激活受体α/δ（PPARα/δ）被认为是非酒精性脂肪性肝炎（NASH）的潜在治疗靶点。然而，PPARα/δ双重激动剂GFT-505在III期临床试验中表现出较差的抗NASH效果，这可能是由于其PPARα/δ激动活性较弱且代谢稳定性差。其他报道的 PPARα/δ 双重激动剂要么表现出有限的效力，要么具有不平衡的 PPARα/δ 激动活性。在此，我们报道了一系列新型三唑酮衍生物作为 PPARα/δ 双重激动剂。其中，化合物H11在 PPAR 反式激活测定中表现出有效且平衡的 PPARα/δ 激动活性（PPARα EC 50 = 7.0 nM；PPARδ EC 50 = 8.4 nM）以及对 PPARγ 的高选择性（PPARγ EC 50 = 1316.1 nM）。 PPARδ 与H11复合物的晶体结构揭示了独特的 PPARδ-激动剂相互作用。 H11具有优异的 PK 特性和良
• Phenyloxyalkanonic acid derivatives as hppar activators
  申请人：Dodic Nerina

  公开号：US20050222424A1

  公开（公告）日：2005-10-06

  A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:

  化合物公式(I)或其药学上可接受的盐、溶剂化物或可水解酯，其中：
• Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1)
  作者：Yoshihiro Shibata、Katsuji Kagechika、Mitsuhiro Yamaguchi、Hideo Kubo、Hiroyuki Usui

  DOI：10.1016/j.bmcl.2012.09.092

  日期：2012.12

  We describe here the design, syntheses and structure-activity relationships (SAR) of novel zwitterionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) alpha/gamma dual agonists. We commenced the medicinal research with compound 1 originated by Eli Lilly, which was reported to possess PPAR alpha/gamma dual agonist activity. We incorporated an amine linker and optimized it on the nitrogen of the linker, thereby envisioning the enhancement of the PPAR alpha/gamma dual agonist activity together with altering the physicochemical properties. As a result, we could generate compounds showing the PPAR alpha/gamma dual activity, especially among which compound 22e had a franylmethyl group on the linker and 2,6-dimethyl phenyl ring at the carboxylic acid head group furnishing a highly potent dual agonist activity, together with a great glucose lowering effect. Moreover, it remedied the lipid profile, that is, triglyceride without body weight gain in the db/db mice model. (C) 2012 Elsevier Ltd. All rights reserved.
• Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects
  作者：Yunyuan Huang、Lin Wei、Xinya Han、Haifeng Chen、Yanliang Ren、Yanhong Xu、Rongrong Song、Li Rao、Chen Su、Chao Peng、Lingling Feng、Jian Wan

  DOI：10.1016/j.ejmech.2019.111749

  日期：2019.12

  Fructose-1,6-bisphosphatase (FBPase) is an essential enzyme of GNG pathway. Significant advances demonstrate the FBPase plays a critical role in treatment of diabetes. Numerous FBPase inhibitors were developed by targeting AMP site, nevertheless, none of these inhibitors has exhibited suitable potency and druggability. Herein, a new allosteric site (C128) on FBPase was discovered, and several nitrostyrene compounds exhibiting potent FBPase inhibitions were found covalently bind to C128 site on FBPase. Mutagenesis suggest that C128 is the only cysteine that can influence FBPase inhibition, the N125-S124-S123 pathway was most likely involved in allosteric signaling transmission between C128 and active site. However, these nitrostyrenes may bind with multiple cysteine besides C128 in FBPase. To improve pocket selectivity, a series of novel compounds (14a-14n) were re-designed rationally by integrating fragment-based covalent virtual screening and machine-learning-based synthetic complexity evaluation. As expected, the mass spectrometry validated that the proportion of title compounds binding to the C128 in FBPase was significantly higher than that of nitrostyrenes. Notably, under physiological and pathological conditions, the treatment of compounds 14b, 14c, 14i or 14n led to potent inhibition of glucose production, as well as decreased triglyceride and total cholesterol levels in mouse primary hepatocytes. We highlight a novel paradigm that molecular targeting C128 site on FBPase can have potent hypoglycemic effect. (C) 2019 Elsevier Masson SAS. All rights reserved.
• PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1513796B1

  公开（公告）日：2008-02-13